Clinical Outcome and Management of Ureteral Obstruction Secondary to Gastric Cancer

Migita, Kazuhiro; Watanabe, Akihiko; Samma, Shoji; Ohyama, Takao; Ishikawa, Hirofumi; Kagebayashi, Yoriaki

doi:10.1007/s00268-011-1016-8

Cited by 15 publications

(25 citation statements)

References 20 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This review of 57 papers gives a broad survival range for patients with malignant ureteric obstruction; between 21 hours and 140 months (1,3,(8)(9)(10)(11)15,(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)54,(56)(57)(58)(59)(61)(62)(63). The median survival was 6.4 months and the percentage of patients alive at one year was 23% (3,9,10,23,24,28,32,38,44). Reasons for this variation in survival include the heterogeneous patient and cancer groups involved.…”

Section: Discussionmentioning

confidence: 99%

“…Sixteen papers with a total of 2061 patients investigated various factors and their ability to prognosticate (3,9,10,23,24,27,29,30,35,37,41,53,60,(69)(70)(71) in these patients.…”

Section: Prognostication Toolsmentioning

confidence: 99%

“…These were found to include low serum albumin (10,29,35,41,71), no further treatment options (3,23,37,53), hyponatraemia (29,35), number of malignancy related events (pleural effusion, metastatic disease, ascites) (10,29,35,41), the presence of metastatic disease (27,60), performance status of 2 or worse on the European cooperative cancer group (ECOG) (9,23,53,71).…”

Section: Prognostication Toolsmentioning

confidence: 99%

“…The most frequently found statistically significant indicators of poor prognosis were low serum albumin (10,29,35,41,71), no further treatment options (3,23,37,53), number of malignancy related events (pleural effusion, metastatic disease, ascites) (10,29,35,41), performance status of 2 or worse on the European cooperative cancer group (ECOG) (9,23,53,71), the presence of metastatic disease (27,60), and hyponatremia (29,35). Two papers divided patients into groups depending on treatment options available; those with no treatment options had 0% 12 month survival and a median survival of 38 days (69,70).…”

Section: Prognosticationmentioning

confidence: 99%

“…An obstructed single system can significantly reduce patients' quality of life of patients especially if infection ensues, however, bilateral obstruction will lead to a certain death. In fact upper urinary tract obstruction is a prognostic indicator of morbidity for many cancers (1)(2)(3).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Malignant ureteric obstruction decompression: how much gain for how much pain? A narrative review

et al. 2018

View full text Add to dashboard Cite

Over the last thirty years, the management of Malignant Ureteric Obstruction (MUO) has evolved from a single disciplinary decision to a multi-disciplinary approach. Careful consideration must be given to the risks and benefits of decompression of hydronephrosis for an individual patient. There is a lack of consensus of opinion as well as strong evidence to support the decision process. Outcomes that were identified amongst patients undergoing treatment for MUO included prognosis, quality of life (QOL), complications, morbidity and prognostication tools. A total of 63 papers were included. Median survival was 6.4 months in the 53 papers that stated this outcome. Significant predictors to poor outcomes included low serum albumin, hyponatremia, the number of malignancy related events, and performance status of 2 or worse on the European cooperative cancer group. We propose a multi-centre review of outcomes to enable evidence-based consultations for patients and their families.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Sixteen papers with a total of 2061 patients investigated various factors and their ability to prognosticate (3,9,10,23,24,27,29,30,35,37,41,53,60,(69)(70)(71) in these patients.…”

Section: Prognostication Toolsmentioning

confidence: 99%